|Mr. Alain Moussy MBA||Co-Founder, Chairman, Pres, CEO, MD & Scientific Director||645.57k||N/A||N/A|
|Mr. Denis Gicquel||Deputy CEO & Head of Pharmaceutical Devel.||103.79k||N/A||N/A|
|Mr. Laurent Guy MBA||Chief Financial Officer||N/A||N/A||N/A|
|Mr. Christian FASSOTTE||Global Chief Medical Officer||N/A||N/A||N/A|
|Mr. Alexis BERNARD||Head of Veterinary Sales||N/A||N/A||N/A|
|Ms. Catherine ARGILLIER||Head of Quality Assurance||N/A||N/A||N/A|
|Mr. Harshad KULKARNI||Head of Statistics||N/A||N/A||N/A|
|Mr. Antonello CERVONE||Head of Data Management & IT Director||N/A||N/A||N/A|
|Dr. Yves Grumser M.D.||Head of Clinical Safety & Pharmacovigilance||N/A||N/A||N/A|
|Ms. Veronique Gelebart||Head of Clinical Operations & Clinical Devel.||N/A||N/A||N/A|
AB Science S.A., a clinical-stage pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
AB Science S.A.’s ISS governance QualityScore as of 1 May 2022 is 10. The pillar scores are Audit: 10; Board: 8; Shareholder rights: 7; Compensation: 9.